← Leaderboards
Victor Nizet
University Of California, San Diego
$31,303,620
Attributed
$49,457,259
Total exposure
28
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $11.5M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$67,227,469 · 31
By mechanism
R01$33,994,907 · 13
P50$16,865,225 · 5
T32$4,449,462 · 2
U54$4,183,648 · 3
R37$4,037,523 · 1
P01$1,826,257 · 1
Top collaborators
- Adriana H Tremoulet18 shared
- Richard L Gallo12 shared
- Partho Ghosh9 shared
- Lars Bode8 shared
- Christina Chambers8 shared
- Shirley M Tsunoda8 shared
- Randall S Johnson6 shared
- Ethan Bier5 shared
Most similar at University Of California, San Diego
Same institution · by research overlap
- Partho Ghosh$14,796,209
- Monika Kumaraswamy$947,313
- Mark Joseph Walker$999,858
- Liangfang Zhang$5,562,722
- Angela Meier$1,009,165
Others in their field
Top investigators on “Pathogen”
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$343,790,695
- Richard Webby · St. Jude Children'S Research Hospital$265,067,789
- Jeffrey P Krischer · University Of South Florida$130,496,919
- Mark S Klempner · Tufts Medical Center$128,021,180
- Timothy Stedman · American Type Culture Collection$122,230,581
- Adolfo Garcia-Sastre · Icahn School Of Medicine At Mount Sinai$99,962,183
Research focus
PathogenInfectionImmuneResponseNeutrophilIn VivoMouse ModelInflammatoryPathogenesisMacrophageNatural ImmunityResearch PersonnelStreptococcus PyogenesComplementSepsisVirulenceVirulence FactorsBacteriaSkinLifeMicrobialPathway InteractionsAntibioticsCommunicable Diseases
Grant awards (123)
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses$1,190,453
P50 · FY2025 · HD
Biomimetic Macrophage Membrane-Coated Nanosponges: A Novel Therapeutic for Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii Hospital-Associated Pneumonia$991,226
R01 · FY2025 · AI · contact PI
Combating Antibiotic Resistance Into the Next Generation (CARING)$669,590
T32 · FY2025 · AI · contact PI
Identifying the Most Effective Adjuvant(s) for Leading Group A Streptococcal Vaccine Antigens in Preclinical Mouse and Nonhuman Primate Models$635,274
R01 · FY2025 · AI · contact PI
Cathelicidin in Skin Immunity$607,167
R37 · FY2025 · AI
The impact of ampicillin and breast milk oligosaccharides on the infant microbiome and immune functions$201,617
P50 · FY2025 · HD · contact PI
Academic Training in Therapeutic Advancement for Child Health (ATTACH)$189,669
T32 · FY2025 · HD
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses$3,465,000
P50 · FY2024 · HD
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses$3,465,000
P50 · FY2024 · HD
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses$1,231,207
P50 · FY2024 · HD
Biomimetic Macrophage Membrane-Coated Nanosponges: A Novel Therapeutic for Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii Hospital-Associated Pneumonia$1,009,268
R01 · FY2024 · AI · contact PI
Identifying the Most Effective Adjuvant(s) for Leading Group A Streptococcal Vaccine Antigens in Preclinical Mouse and Nonhuman Primate Models$658,644
R01 · FY2024 · AI · contact PI
Cathelicidin in Skin Immunity$611,296
R37 · FY2024 · AI
Combating Antibiotic Resistance Into the Next Generation (CARING)$605,609
T32 · FY2024 · AI · contact PI
Academic Training in Therapeutic Advancement for Child Health (ATTACH)$207,813
T32 · FY2024 · HD
The impact of ampicillin and breast milk oligosaccharides on the infant microbiome and immune functions$202,633
P50 · FY2024 · HD · contact PI
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses$1,239,102
P50 · FY2023 · HD
Biomimetic Macrophage Membrane-Coated Nanosponges: A Novel Therapeutic for Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii Hospital-Associated Pneumonia$1,027,000
R01 · FY2023 · AI · contact PI
Identifying the Most Effective Adjuvant(s) for Leading Group A Streptococcal Vaccine Antigens in Preclinical Mouse and Nonhuman Primate Models$705,798
R01 · FY2023 · AI · contact PI
C3-Dependent Intracellular Killing in Innate Immunity and Bacterial Pathogenesis$626,584
R01 · FY2023 · AI
Cathelicidin in Skin Immunity$545,680
R37 · FY2023 · AI
Combating Antibiotic Resistance Into the Next Generation (CARING)$543,416
T32 · FY2023 · AI · contact PI
Surprising Efficacy of Discounted Antibiotics vs. MDR Gram-Negative Pathogens Occurring Through Innate Immune Sensitization$474,000
R01 · FY2023 · AI · contact PI
The impact of ampicillin and breast milk oligosaccharides on the infant microbiome and immune functions$203,577
P50 · FY2023 · HD · contact PI
Academic Training in Therapeutic Advancement for Child Health (ATTACH)$170,771
T32 · FY2023 · HD
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses$1,250,000
P50 · FY2022 · HD
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses$1,015,736
P50 · FY2022 · HD
C3-Dependent Intracellular Killing in Innate Immunity and Bacterial Pathogenesis$627,952
R01 · FY2022 · AI
Combating Antibiotic Resistance Into the Next Generation (CARING)$571,496
T32 · FY2022 · AI · contact PI
Cathelicidin in Skin Immunity$555,527
R37 · FY2022 · AI
Surprising Efficacy of Discounted Antibiotics vs. MDR Gram-Negative Pathogens Occurring Through Innate Immune Sensitization$474,000
R01 · FY2022 · AI · contact PI
The impact of ampicillin and breast milk oligosaccharides on the infant microbiome and immune functions$200,737
P50 · FY2022 · HD · contact PI
Academic Training in Therapeutic Advancement for Child Health (ATTACH)$153,437
T32 · FY2022 · HD
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses$1,250,000
P50 · FY2021 · HD
C3-Dependent Intracellular Killing in Innate Immunity and Bacterial Pathogenesis$628,647
R01 · FY2021 · AI
Cathelicidin in Skin Immunity$564,676
R37 · FY2021 · AI
Surprising Efficacy of Discounted Antibiotics vs. MDR Gram-Negative Pathogens Occurring Through Innate Immune Sensitization$474,000
R01 · FY2021 · AI · contact PI
Combating Antibiotic Resistance Into the Next Generation (CARING)$427,360
T32 · FY2021 · AI · contact PI
Glycan-Lectin Receptor Regulation of Macrophage Maturation and Lung InnateDefenses in the Fetus and Newborn Infant$348,400
R01 · FY2021 · AI
The impact of ampicillin and breast milk oligosaccharides on the infant microbiome and immune functions$205,146
P50 · FY2021 · HD · contact PI
Academic Training in Therapeutic Advancement for Child Health (ATTACH)$155,369
T32 · FY2021 · HD
Pediatric and Developmental Pharmacology for Inflammatory and Infectious Diseases$711,940
P50 · FY2020 · HD
C3-Dependent Intracellular Killing in Innate Immunity and Bacterial Pathogenesis$628,663
R01 · FY2020 · AI
Cathelicidin in Skin Immunity$569,384
R37 · FY2020 · AI
Surprising Efficacy of Discounted Antibiotics vs. MDR Gram-Negative Pathogens Occurring Through Innate Immune Sensitization$472,625
R01 · FY2020 · AI · contact PI
Glycan-Lectin Receptor Regulation of Macrophage Maturation and Lung Innate Defenses in the Fetus and Newborn Infant$438,633
R01 · FY2020 · AI
Research in Infectious Disease$393,010
T32 · FY2020 · AI · contact PI
Pharmacological Modulation of IL-1beta/Inflammasome Signaling and Host Immunity to Bacterial Pathogens$153,035
P50 · FY2020 · HD · contact PI
Pediatric and Developmental Pharmacology for Inflammatory and Infectious Diseases$722,489
P50 · FY2019 · HD
C3-Dependent Intracellular Killing in Innate Immunity and Bacterial Pathogenesis$629,334
R01 · FY2019 · AI
Cathelicidin in Skin Immunity$583,793
R37 · FY2019 · AI
Glycan-Lectin Receptor Regulation of Macrophage Maturation and Lung Innate Defenses in the Fetus and Newborn Infant$441,188
R01 · FY2019 · AI
GAS Switch from Colonizing Bacterium to Invasive Pathogen$364,000
R01 · FY2019 · AI · contact PI
Research in Infectious Disease$361,922
T32 · FY2019 · AI · contact PI
Broad recognition of group A Streptococcus M proteins$193,750
R21 · FY2019 · AI
Pharmacological Modulation of IL-1beta/Inflammasome Signaling and Host Immunity to Bacterial Pathogens$157,553
P50 · FY2019 · HD · contact PI
Pediatric and Developmental Pharmacology for Inflammatory and Infectious Diseases$734,233
U54 · FY2018 · HD
Glycoprotein Remodeling in the Vasculopathy and Coagulopathy of Sepsis$674,012
R01 · FY2018 · HL
Mechanisms of the M protein in group A Streptococcus virulence$539,835
R56 · FY2018 · AI
Analyzing a novel mechanism of action of bacterial cAMP producing toxins$537,892
R01 · FY2018 · AI
GAS Switch from Colonizing Bacterium to Invasive Pathogen$364,000
R01 · FY2018 · AI · contact PI
Broad recognition of group A Streptococcus M proteins$232,500
R21 · FY2018 · AI
Pharmacological Modulation of IL-1beta/Inflammasome Signaling and Host Immunity to Bacterial Pathogens$161,831
U54 · FY2018 · HD · contact PI
2018 Streptococcal Biology Gordon Research Conference$8,500
R13 · FY2018 · AI · contact PI
Pediatric and Developmental Pharmacology for Inflammatory and Infectious Diseases$738,651
U54 · FY2017 · HD
Glycoprotein Remodeling in the Vasculopathy and Coagulopathy of Sepsis$693,643
R01 · FY2017 · HL
Analyzing a novel mechanism of action of bacterial cAMP producing toxins$537,892
R01 · FY2017 · AI
Cathelicidin in Skin Immunity$387,500
R01 · FY2017 · AI
GAS Switch from Colonizing Bacterium to Invasive Pathogen$364,000
R01 · FY2017 · AI · contact PI
Microbial Glycan Mimicry and Glycosidases in Inflammatory Responses$278,586
P01 · FY2017 · HL · contact PI
Pharmacological Modulation of IL-1beta/Inflammasome Signaling and Host Immunity to Bacterial Pathogens$147,526
U54 · FY2017 · HD · contact PI
Pediatric and Developmental Pharmacology for Inflammatory and Infectious Diseases$756,399
U54 · FY2016 · HD
Glycoprotein Remodeling in the Vasculopathy and Coagulopathy of Sepsis$712,652
R01 · FY2016 · HL
Analyzing a novel mechanism of action of bacterial cAMP producing toxins$537,892
R01 · FY2016 · AI
Cathelicidin in Skin Immunity$387,500
R01 · FY2016 · AI
GAS Switch from Colonizing Bacterium to Invasive Pathogen$364,000
R01 · FY2016 · AI · contact PI
Microbial Glycan Mimicry and Glycosidases in Inflammatory Responses$278,560
P01 · FY2016 · HL · contact PI
Pharmacological Modulation of IL-1beta/Inflammasome Signaling and Host Immunity to Bacterial Pathogens$151,280
U54 · FY2016 · HD · contact PI
Boosting Innate Immunity Through HIF to Treat Antibiotic-Resistant Infections$966,226
R01 · FY2015 · AI · contact PI
Glycoprotein Remodeling in the Vasculopathy and Coagulopathy of Sepsis$720,159
R01 · FY2015 · HL
Analyzing a novel mechanism of action of bacterial cAMP producing toxins$537,892
R01 · FY2015 · AI
Mechanisms of the M protein in group A Streptococcus virulence$513,230
R01 · FY2015 · AI
Cathelicidin in Skin Immunity$387,500
R01 · FY2015 · AI
GAS Switch from Colonizing Bacterium to Invasive Pathogen$377,750
R01 · FY2015 · AI · contact PI
Microbial Glycan Mimicry and Glycosidases in Inflammatory Responses$268,736
P01 · FY2015 · HL · contact PI
Boosting Innate Immunity Through HIF to Treat Antibiotic-Resistant Infections$973,816
R01 · FY2014 · AI · contact PI
Glycoprotein Remodeling in the Vasculopathy and Coagulopathy of Sepsis$766,997
R01 · FY2014 · HL
Analyzing a novel mechanism of action of bacterial cAMP producing toxins$537,892
R01 · FY2014 · AI
Mechanisms of the M protein in group A Streptococcus virulence$522,395
R01 · FY2014 · AI
Cathelicidin in Skin Immunity$387,500
R01 · FY2014 · AI
Microbial Glycan Mimicry and Glycosidases in Inflammatory Responses$243,447
P01 · FY2014 · HL · contact PI
Boosting Innate Immunity Through HIF to Treat Antibiotic-Resistant Infections$922,225
R01 · FY2013 · AI · contact PI
Optimizing phagocyte activity against antibiotic resistant pathogens$761,943
U54 · FY2013 · AI · contact PI
Mechanisms of the M protein in group A Streptococcus virulence$562,436
R01 · FY2013 · AI
Cathelicidin in Skin Immunity$364,250
R01 · FY2013 · AI
Microbial Glycan Mimicry and Glycosidases in Inflammatory Responses$247,625
P01 · FY2013 · HL · contact PI
Boosting Innate Immunity Through HIF to Treat Antibiotic-Resistant Infections$994,866
R01 · FY2012 · AI · contact PI
Optimizing phagocyte activity against antibiotic resistant pathogens$731,785
U54 · FY2012 · AI · contact PI
Mechanisms of the M protein in group A Streptococcus virulence$524,859
R01 · FY2012 · AI
GAS Switch from Colonizing Bacterium to Invasive Pathogen$408,056
R01 · FY2012 · AI · contact PI
Microbial Glycan Mimicry and Glycosidases in Inflammatory Responses$252,623
P01 · FY2012 · HL · contact PI
Mechanisms of the M protein in group A Streptococcus virulence$71,029
R01 · FY2012 · AI
Boosting Innate Immunity Through HIF to Treat Antibiotic-Resistant Infections$1,036,121
R01 · FY2011 · AI · contact PI
Mechanisms of the M protein in group A Streptococcus virulence$532,847
R01 · FY2011 · AI
GAS Switch from Colonizing Bacterium to Invasive Pathogen$406,406
R01 · FY2011 · AI · contact PI
Microbial Glycan Mimicry and Glycosidases in Inflammatory Responses$256,680
P01 · FY2011 · HL · contact PI
Boosting Innate Immunity Through HIF to Treat Drug-Resistant Bacterial Infections$703,902
R56 · FY2010 · AI · contact PI
GAS Switch from Colonizing Bacterium to Invasive Pathogen$404,898
R01 · FY2010 · AI · contact PI
Sialic Acid O-Acetylation in GBS Pathogenesis & Immunity$291,098
R01 · FY2010 · HD · contact PI
GAS Switch from Colonizing Bacterium to Invasive Pathogen$407,376
R01 · FY2009 · AI · contact PI
Sialic Acid O-Acetylation in GBS Pathogenesis & Immunity$294,038
R01 · FY2009 · HD · contact PI
Sialic Acid O-Acetylation in GBS Pathogenesis & Immunity$79,997
R01 · FY2009 · HD · contact PI
GAS Switch from Colonizing Bacterium to Invasive Pathogen$371,146
R01 · FY2008 · AI · contact PI
Sialic Acid O-Acetylation in GBS Pathogenesis & Immunity$294,038
R01 · FY2008 · HD · contact PI
Sialic Acid O-Acetylation in GBS Pathogenesis & Immunity$300,039
R01 · FY2007 · HD · contact PI
Sialic Acid O-Acetylation in GBS Pathogenesis & Immunity$308,750
R01 · FY2006 · HD · contact PI
SLS: Molecular Basis and Role in Invasive GAS Disease$296,856
R01 · FY2006 · AI · contact PI
SLS: Molecular Basis and Role in Invasive GAS Disease$304,000
R01 · FY2005 · AI
SLS: Molecular Basis and Role in Invasive GAS Disease$304,000
R01 · FY2004 · AI
SLS: Molecular Basis and Role in Invasive GAS Disease$304,000
R01 · FY2003 · AI
SLS: Molecular Basis and Role in Invasive GAS Disease$304,000
R01 · FY2002 · AI
MOLECULAR BASIS OF LUNG INJURY IN GBS PNEUMONIA$116,210
K08 · FY2000 · AI
PENETRATION OF THE BLOOD BRAIN BARRIER IN GBS MENINGITIS$75,750
R03 · FY2000 · HD